ferroptosis
ferroptosis
Overview
Ferroptosis is a form of regulated cell death characterized by the accumulation of lipid peroxides to lethal levels, which is distinct from other forms of cell death such as apoptosis and necroptosis. This iron-dependent process is driven by oxidative stress and is implicated in various physiological and pathological conditions, including cancer, neurodegeneration, and organ damage. The mechanism of ferroptosis involves the depletion of glutathione (GSH), a critical antioxidant, and the inactivation of glutathione peroxidase 4 (GPX4), leading to increased reactive oxygen species (ROS) and subsequent lipid peroxidation. Given its role in tumor suppression and disease progression, ferroptosis has emerged as a promising therapeutic target in cancer treatment and other diseases.
Focus of Latest Publications
Recent research demonstrates ferroptosis as a promising therapeutic target across multiple cancer types and disease states. In oncology, ferroptosis induction has been evaluated in triple-negative breast cancer using the repurposed antiparasitic nitazoxanide, in hepatocellular carcinoma through exosome-like nanovesicles and natural compounds like noni juice, and in gastric, bladder, and pancreatic cancers via multiple pharmacological and nanomaterial-based approaches. Notably, pulmonary sarcomatoid carcinoma exhibits an elevated ferroptosis suppression signature, suggesting vulnerability to ferroptosis-inducing strategies targeting iron transporters and glutathione metabolism. These studies collectively identify ferroptosis induction as a mechanism to overcome therapeutic resistance in malignancies ranging from lung carcinomas to osteosarcomas.
The molecular basis of ferroptosis-based therapeutics consistently involves disruption of iron homeostasis and the antioxidant defense system. Multiple studies document that effective ferroptosis induction occurs through downregulation of GPX4 and SLC7A11, depletion of glutathione, accumulation of intracellular iron, elevated reactive oxygen species, and lipid peroxidation with associated mitochondrial damage. The Nrf2/HO-1-GPX4 and Nrf2/SLC7A11 signaling axes emerge as central regulatory nodes, with diverse therapeutic agents—ranging from natural polyphenols and traditional medicine formulations to engineered nanoparticles—converging on these pathways to initiate ferroptotic cell death.
A critical emerging insight is the synergy between ferroptosis and anti-tumor immunity. GALNT7-dependent ferroptosis suppression was identified as a mechanism of immunotherapy resistance in non-small cell lung cancer, and its silencing enhanced CD8+ T cell infiltration and interferon-gamma production while sensitizing tumors to anti-PD-1 therapy. Ferroptosis operates as an immunogenic cell death modality distinct from apoptosis, generating danger signals that activate dendritic cells and T-lymphocytes, thereby converting "cold" immune-excluded tumors into responsive states amenable to checkpoint inhibition and establishing immunological memory.
Beyond oncology, ferroptosis modulation addresses neurodegenerative and inflammatory pathologies. In Parkinson's disease, ferroptosis represents a key driver of dopaminergic neuronal degeneration, and targeted iron-chelating and antioxidant nanotherapeutics restored neuronal viability and motor function in models. In Alzheimer's disease, impaired mitophagy disrupts redox and iron homeostasis, increasing neuronal susceptibility to ferroptosis in a self-amplifying cycle. Additional therapeutic applications include attenuation of hepatic fibrosis through microbiota-dependent ferroptosis inhibition, amelioration of radiation enteritis via engineered probiotics, and reduction of myocardial injury in obesity-related cardiomyopathy through ferroptosis suppression.
Therapeutic delivery platforms have diversified to include natural product derivatives, exosome-based carriers, metal-organic framework nanocomposites with calcium overload capacity, photodynamic-ferroptotic hybrid nanomaterials, and genetically engineered probiotic systems. These strategies leverage the elevated oxidative stress microenvironment of target pathological cells—whether senescent, cancerous, or inflammatory—to achieve selective ferroptosis induction while sparing healthy tissues, thereby improving therapeutic safety and efficacy.